Semikarbazon – svestrani farmakofor u dizajniranju antikonvulziva by SURENDRA NATH PANDEYA
Epilepsy is a brain disorder that causes people to have recurring seizures. Epilepsy
affects 50 million people worldwide, and 50 % of them live in the developing world (1, 2).
Many options are available, from different chemical classes such as hydantoins (3)
barbiturates (4), benzodiazepines (5), gamma-aminobutyric acid (GABA) analogs (6), di-
benzepines (7) and carbamates (8). All of these compounds are used in the treatment of
epilepsy. All these medications suffer from having many side effects. Therefore, it has
become necessary to discover new chemical pharmacophores with a broad spectrum of
activity and less neurotoxicity.
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During the last fifteen years, semicarbazones have been
extensively investigated for their anticonvulsant proper-
ties. 4-(4-Flurophenoxy) benzaldehyde semicarbazone
(C0102862, V102862) was discovered as a lead molecule
and is being developed as a potent antiepileptic drug,
with maximal electroshock (MES) ED50 of i.p. 12.9 mg
kg1. In MES (oral screen), this compound has a protec-
tive index (PI = TD50/ED50 > 315) higher than carbama-
zepine (PI 101), phenytoin (PI > 21.6) and valproate (PI
2.17). The compound is a potent sodium channel blocker.
Other semicarbazones have demonstrated activity in va-
rious chemoshock screens, like subcutaneous pentylene-
tetrazole, subcutaneous strychnine, subcutaneous picro-
toxin and subcutaneous bicculine. Semicarbazones are
also GABA-transaminase inhibitors. Extensive structure-
-activity relationship has demonstrated that F, Cl, Br and
NO2 substituents in the arylhydrophobic pocket and a
hydrogen bonding domain (HBD) are generally found in
active anticonvulsant agents.
Keywords: semicarbazone, anticonvulsant, Na+ channel
blocker
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Many new pharmacophores have been developed over the last twenty years. Func-
tionalized amino acids and alpha-amino amides are two classes of antiepileptic drugs
(AEDs) that exhibit pronounced anticonvulsant activity (9). Lacosamide (10) and safina-
mide (11) are two recently launched AEDs resulting from this approach. Enaminones
have been extensively investigated as anticonvulsants (12). In this review, advances
made in the application of semicarbazones as a versatile pharmacophore model for the
design of new anticonvulsant drugs are updated. Some reviews on the biological activ-
ity of semicarbazones and thiosemicarbazones (13) and their metal complexes (14) are
mentioned.
Evolution of the concept of semicarbazones as anticonvulsants
The semicarbazone moiety is made up of several smaller functional groups exhibit-
ing anticonvulsant activity (Fig. 1).
Carboxamides as anticonvulsants
Several carboxamides have been launched on the market. The early drug carbama-
zepine (15) is the drug of choice for the treatment of grandmal epilepsy and is effective
against temporal lobe and generalized seizures. Modification of the drug has resulted in
oxacarbazepine (16) and eslicarbamazepine (17), the two most clinically effective drugs
for the treatment of epilepsy (Fig. 2).
Progabide (18) is the first GABA agonist that is effective in all the three types of epi-
lepsy, generalized tonic-clonic, myoclonic, and partial seizures in both children and
adults.
Hydrazones as anticonvulsants
A series of 3-aryloxy/arylthiooxyacetylhydrazono-3,2-indolines revealed varying
degrees of activity against subcutaneous pentylenetetrazole (ScPTZ) induced seizures
(19). Anticonvulsant activity of hydrazones, Schiff bases and Mannich bases of isatine
were recorded (20). Indole-3-carboxaldehyde hydrazones exhibited low levels of anti-
convulsant activity (21). Recently, (±)-3-menthone aryl acid hydrazones afforded signifi-
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Fig. 1. Concept of semicarbazones as anticonvulsants.
cant protection in the maximal clonic seizure screen at 6 Hz. 4-Chloro-N-(2-isopropyl-
5-methylcyclohexylidene) benzohydrazide was active in maximal electroshock seizure
(MES) ED50 of 16.1 mg kg1 and protective index (PI = TD50/ED50) greater than 20 (22)
(Fig. 3).
Urea derivatives as anticonvulsant acyclic/cyclic derivatives
In the early days, acyclic ureas and cyclic ureides demonstrated potent anticonvul-
sant activity. Many of them are still preferred drugs for the treatment of epilepsy (23).
Phenacemide (24), hydantoin derivatives, phenytoin (23) and its water soluble prodrug
fosphenytoin (25) are used in hospitals for the treatment of epileptic seizures. A succin-
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Fig. 3. Hydrazone anticonvulsants.
imide derivative ethosuximide (26) is considered the first choice drug for treating ab-
sence seizures. Phenobarbital (27) is a barbiturate and is the most widely used anticon-
vulsant worldwide. Its N-CH3 analog, methylphenobarbital, is used as an anticonvul-
sant. Primidone is used for generalized tonic-clonic and complex seizures (Fig. 4).
Dimmock’s early work on semicarbazones
A major achievement of Dimmock (28) was the identification of 4-(4’-fluoropheno-
xy) benzaldehyde semicarbazone as a lead molecule. Derivatives of this molecule were
highly potent and were patented (29). The anticonvulsant activity of some compounds is
presented in Table I. The majority of compounds demonstrated no neurotoxicity upto
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Phenobarbital R = H
Methyl phenobarbital R = CH3
Fig. 4. Acyclic and cyclic ureides.
Table I. Anticonvulsant activity of substituted phenoxybenzaldehyde semicarbazones
R X ED(50) Ref.
H O 1.5 30
H S 1.5 30
F O 2.5 30
F S 2.5 30
Cl O 1.0 30
Cl S 1.0 30
Br O 2.0 30
Br S 1.5 30
ED50: MES (rat, oral)
R X CH=NNHCONH2
doses of 500 mg kg1. Among the phenoxybenzaldehyde analogs, halobenzosubstituted
derivatives were the most active ones. Further exploring the structural changes, various
heterocyclic, carbocyclic and fused rings were introduced in the molecule in place of the
aryloxy group (31).
The heterocycles included thiophene, pyrrole, furan, imidazole, pyridine, pyrazine,
pyrimidine, phenothiazine, quinoline, indole, benzoxazole and benzimidazole. The car-
bocyclic groups included cyclohexyl and cycloheptyl. 4-(3,4-Methyleneoxyphenoxy)
benzaldehyde semicarbazone had MES (mice, p.o.) ED50 of 5.3 mg kg1. Several other
substituents showed promising activity and ability to inhibit human skeletal muscles.
Na+ subchannel subunit stable expression in HEK-293 cells was studied (Table II) (29).
Since 4-(4-fluorophenoxy) benzaldehyde semicarbazone metabolizes to the corres-
ponding semicarbazide, some novel substituted semicarbazides were prepared (Fig. 5)
and found active (32). Semicarbazide is a base due to the presence of basic N-1 nitrogen;
semicarbazone is not a base but the NH group on N-2 nitrogen is slightly acidic. The
C=N bond in semicarbazone makes it a relatively rigid structure while the –C-N- single
bond in semicarbazide is relatively non-rigid and affects the molecule bioactivity.
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R = H, F, Cl, Br, OCH3, CF3, CH3, NO2, t-butyl, C3H7, s-butyl, cyclohexyl, cycloheptyl, 3-methyl
3,4-methylene dioxy, 5-indanyl, 3,5-diF, 3,4-diF
R’ = F; R”’ = CH3
R” = CH3
Fig. 5. Aryloxyphenyl semicarbazides.
Table II. Na+channel binding of semicarbazones
Ar ED50 MES (i.p.) (mg kg1) KI(M) mg kg1 Ref.
1.1 29
5-indanyl 0.04 1.7 29
cycloheptoxy 0.25 3.2 29
0.2 1.6 31
6 14.9 31
ED50 (MES i.p. ranged from 0.13 to 7.5 mg kg1) and KI(M) from 0.9–3.4 mg kg1.





Pandeya et al. (33) synthesized thiouriedo derivatives of acetophenone semicarba-
zone. Compound 4-(N’-methylthioureido)acetophenone had MES (i.p.) ED50 23.5 mg
kg1 compared to phenytoin with ED50 of 23.2 mg kg1. This compound has a better pro-
tective index (PI = TD50/ED50) than sodium valproate (2.55 vs. 2.17) and was also active
in the subcutaneous pentylenetetrazole (ScPTZ) test (Fig. 6).
A rigid analog of semicarbazone linker was prepared. 2-[4-(4-Chlorophenyl-2-fluo-
rophenoxy)phenyl]-pyrimidine-4-carboxamide was found to be a potent, broad spec-
trum state-dependent sodium channel blocker for treating pain states. This compound
was approximately 1000 times more potent, had 2000-fold faster binding kinetics and
10-fold higher levels of state dependence than carbamazepine and lamotrigine. It had
ED50 at least 13 mg kg1 (p.o.) in partial sciatic nerve ligation (34) (Fig. 6).
Pandeya’s modifications of semicarbazone scaffold
Dimmock (35) attempted a structural modification of the primary amino group of
anticonvulsant arylsemicarbazones and found that the primary amino group was not es-
sential. However, its replacement by an aryl ring generally abolished activity, while a
terminal phenyl amino function was better tolerated. Thus, both the size of the group
and its hydrogen bonding capabilities appear to influence bioactivity. Alteration of the
oxygen atom of semicarbazones by isosteres did not enhance anticonvulsant properties.
Considering the observation of Dimmock of the necessity of the terminal carboxa-
mide group to be essential for bioactivity through its involvement in hydrogen bonding
at the putative receptor site, Pandeya et al. (36) modified this terminal carboxamide
function by substituting it with a p-NO2 phenyl group. This preliminary modification
showed anticonvulsant activity at a dose of 30 mg kg1 and ED50 of 83 mg kg1 in the
MES test. This change was further strengthened by the preparation of a series of p-NO2
substituted semicarbazones. 4-(4’-Chlorophenyl)-o-nitrobenzaldehyde was found to be
the most active anticonvulsant agent against MES, ScPTZ and subcutaneous strychnine
(ScSTY) induced seizures. These compounds showed longer duration of action, upto
4.25 h (Fig. 7).
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Fig. 6. Thioureido and levulinic acid semicarbazones, pyrimidine carboxamide and 1,3-dithiolane
semicarbazones.
It appeared at that point of investigation that an aryl ring with an electron with-
drawing substituent was beneficial for the anticonvulsant activity. Therefore, p-chloro-
phenyl group was selected for further modification, because this group is present in di-
azepam, a drug used to treat status epilepticus. A series of p-chlorophenyl substituted
arylsemicarbazones were synthesized and were found active in MES, ScPTZ and ScSTY
tests (37). The majority of compounds showed anticonvulsant activity in all the tests. In
this series, 4-(4’-chlorophenyl)-o-nitrobenzaldehyde semicarbazone was most active. In
this study, the methoxy substituted derivative 4-(4’-chlorophenyl)-3,4-dimethoxybenzal-
dehyde semicarbazone was found orally active in the MES test at a dose of 30 mg kg1,
with no neurotoxicity at that dose. Quantification studies have revealed that 4-(4’-chlo-
rophenyl)-2-methoxybenzaldehyde semicarbazone has MES (mice i.p.) ED50 123.25 mg
kg1; MES (rat, p.o.) ED50 18.55 mg kg1 and 6 Hz (mice, i.p.) ED50 83.93 mg kg1.
Bioisosteric replacement of the chloro atom in N’-(4-chlorophenyl)-N4-2-hydroxy-
benzaldehyde semicarbazone with bromine with higher p values resulted in potent anti-
convulsants. These compounds exerted anticonvulsant activity in MES, ScPTZ and
ScSTY tests. N-(4-bromophenyl) acetophenone semicarbazone protected mice at a dose
of 100 mg kg1 in MES and ScSTY tests. It also protected mice at a dose of 300 mg kg1 in
the ScPTZ screen. N-(4-bromophenyl) acetophenone semicarbazone was not neurotoxic
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Fig. 7. Pandeya’s modification.
Table III. Arylsemicarbazones: substitutions at carboxamide nitrogen
R Ref.
4-F, 4-CH3, 4-Br, 4-Cl, 2-Br, 3-Br, 3-Cl, 5-CH3
2F, 4-Br, 4-F, 4-Cl, 2-Cl
4-SO2NH2, 4-NO2, 4-Br
2, 4-OCH3, 3-Cl-2-CH3, -OC2H5
4-NO2, 4-Cl, 4-SO2NH2







38, 41, 45, 46
4749
37, 5052









at a dose of 300 mg kg1 either. Further, it was orally active at a dose of 30 mg kg1 upto
4 h of drug administration. N-(4-bromophenyl) acetophenone semicarbazone was non-
-sedating either, a property required for a potential anticonvulsant (38).
Encouraged by these results, various other researchers, like Yogeeswari et al. (39
42), introduced several substituents to find out the structure activity relationship be-
tween semicarbazone anticonvulsants (Table III).
Some other researchers have prepared semicarbazones as well; 4-substituted semi-
carbazones of levulinic acid showed anticonvulsant activity (59) (Fig. 6). New a,b and
g-semicarbazones derived from 1,3-dithiolones showed anticonvulsant activity (60) and
one compound (Fig. 6) exhibited agonist activity with regard to PTZ at 250 mg kg1.
Heterocyclic semicarbazones
Siddiqui et al. (57) replaced the phenyl ring of p-chlorophenyl semicarbazones with
a 6-substituted benzothiazole ring to determine the size of the hydrophobic domain.
Rajak et al. (61) introduced the phenyl substituted thiadiazole nucleus in N1-(4-phe-
nyl-1,3,4-thiadiazole-5-benzaldehyde semicarbazone.
Siddiqui et al. (62) synthesized coumarin derived thiazolyl semicarbazones. 4-Bro-
mophenyl (1E)-1-(4-bromophenyl-1-one-N-[4-(2-oxo-2H-chromen-2-yl)-1,3-thiazol-2-yl)
semicarbazone was most potent at a dose of 30 mg kg1 up to 4 h in the MES test. It was
also active against ScPTZ at a dose of 100 mg kg1. However, it was neurotoxic at a dose
of 100 mg kg1 equivalent to phenytoin. Novel quinazolinone semicarbazones displayed
anticonvulsant activity in MES and ScSTY tests at a dose of 30 mg kg1 (63) (Fig. 8).
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Fig. 8. Heterocyclic semicarbazones.
Modifications in the distal aryl ring
The hydrazono terminal has been substituted by a wide spectrum of aldehydes and
ketones having aliphatic, aromatic, alicyclic and heterocyclic moieties (Table IV). From
these studies, three compounds have emerged as the most potent anticonvulsants, which
were investigated in various phases of drug development, 4-fluorophenoxy benzalde-
hyde semicarbazone, 4-bromobenzaldehyde semicarbazone and 3,4-dimethoxy benzal-
dehyde-N4-(p-chlorophenyl) semicarbazone.
4-Fluorophenoxy benzaldehyde semicarbazone displayed MES ED50 (i.p.) 12.9 mg
kg1; ScPTZ > 54 mg kg1, with MES, PI (protective index) of 3.09. This compound was
orally active with very high PI (MES) > 315. The oral ED50 was 1.59 mg kg1. It was more
potent compared to clinically effective drugs such as phenytoin (PI > 21.6), carbamaze-
pine (PI 101) and Na-valproate (PI 2.17) (28).
Dimmock et al. (77) isolated the major inactive urinary metabolite, 4-fluorophenoxy
phenylcarboxy semicarbazide (Fig. 9) from 4-(4-fluorophenoxy) benzaldehyde semicar-
bazone after oral dosing to rats.
On the other hand, Ramu et al. (78) studied the pharmacokinetics of this compound
(C0102862) in rats. Its half-life was 14 days and renal excretion was 74 %. The main me-
tabolite was the corresponding carboxylic acid. They also developed a HPLC method for
the determination of pharmacokinetics of C0102862 in mouse, rat, monkey and dog plas-
ma (79).
Lam (80) patented a large number of substituted phenoxybenzaldehyde semicarba-
zones as anticonvulsants and sodium channel blockers (Fig. 10). Micale et al. (81) studied
the anticonvulsant property of 2-[(4-alkyl semicarbazono-(4-aminophenyl) methyl-4,5-
methylenedioxy phenylacetic acid alkyl esters.
Modification in the semicarbazone linker
The semicarbazones linker provides two essential requirements for anticonvulsant
activity. The carboxamide group is implicated in hydrogen bonding. Pandeya et al. (45)
replaced the CONH-moiety with non-hydrogen bonding –O-CH2– moiety. Whereas
compounds with –CONH– were active in both the MES and ScPTZ tests, compounds
with the –O-CH2– moiety were completely devoid of any anticonvulsant activity, clearly
demonstrating the hydrogen bonding characteristic of the semicarbazono linker (45).
Substitution of the carboxamido hydrogen with ethyl group (68) produced inactive com-
pounds. Continuing the role of –CONH– in hydrogen bonding, however, substitution by
a methyl group produced active compounds, compared to diazepam with a desmethyl
active metabolite.
In another study, phenacylhydrazones lacking the hydrogen bonding characteristic
exhibited no anticonvulsant activity (65) (Fig. 11).
Semicarbazono linker was replaced with a rigid pyrimidine ring to give 2-[4-(4-
chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide (34). This compound was
approximately 1000 times more potent, and had 2000-fold faster binding kinetics than
carbamazepine and lamotrigine tested on recombinant rat Na(v) 1.2 channels and native
Na(+) currents in cultured rat dorsal root ganglion neuron (ED50 13 mg kg1 p.o. in par-
tial nerve ligation).
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Siddiqui et al. (82) synthesized a rigid oxadiazole analog, which was active in the
MES test (i.p.) at 30 mg kg1 up to 0.5 h. Mehta et al. (83) cyclized the semicarbazone
template of an arylsemicarbazone to 4,5-diphenyl-2H-1,2,4-triazole-3(4H)-one. Com-
pound 4-(4-fluorophenyl)-5-(4-nitrophenyl)-2H-1,2,4-triazole-3(4H)-one was active in
MES (10 mg kg1) (i.p.) and ScPTZ (300 mg kg1) screens. This indicates a broad spec-
trum of anticonvulsant activity of cyclized derivatives (83) (Fig. 12).
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R = H, F, Cl, Br, 3,4-diF, 4-Cl, 2F, CF3, NO2, CH3, OCH3, 3-CH3, 3-CH3, 4-C3H7, 5-C4H9, t-C4H9,
3,4-CH-O-O– cC6H11, C7H13, 5-indanyloxy, 6-quinolyoxy.
Fig. 10. Substituted phenoxy/alicyclic/heteroaryl oxybenzaldehyde semicarbazones.
General mechanism of action of anticonvulsants
Most antiepileptic agents possess more than one mechanism of action (84). Antiepi-
leptic drugs can be classified according to the mechanism of action as given below.
Blockade of voltage-dependent sodium or calcium channels.  Phenytoin, carbamazepine,
lamotrigine, oxacarbazepine, topiramate and valproate belong to this group. These drugs
are effective against generalized tonic-clonic and partial seizures.
GABA-mediated anticonvulsants.  Benzodiazepines, gabapentin, tiagabine, vigaba-
trin, topiramate are in this group. Tiagabine inhibits neuronal and glial uptake of GABA,
whilst vigabatrin increases the synaptic concentrations of GABA by inhibiting GABA
aminotransferase. Gabapentin was shown to increase brain synaptic GABA.
Modification of T-type calcium channels.  This class includes only one drug, ethosuxi-
mide, which is active against seizure absences. The mechanism of action of ethosuximi-
de is based on reducing the current in T-type calcium channels found in thalamic nuclei.
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Fig. 11. Modifications in the semicarbazone linker.
Spike-and-wave patterns during petitmal seizures are thought to be initiated in thala-
mocortical relays by activation of these channels. Agents protecting the ScPTZ induced
seizures act by this mechanism.
Mechanism of action of semicarbazone anticonvulsants
Various researchers have studied the mechanism of action of semicarbazones as an-
ticonvulsants. Ilynin et al. (85) found 4-(4-fluorophenoxy) benzaldehyde semicarbazone
(V102862; C0102862) a potent, broad-spectrum blocker of mammalian voltage-gated so-
dium channels. V102862 blocked Na+ currents in acutely dissociated cultured rat hippo-
campal neurons. V102862 was a potent state dependent blocker of r Na 1, 1.2 channels
with a KI (ligand/receptor association constant) of ~ 0.4 mmol L1and KR [binding of the
ligand for resting state (R) of the receptor ~30 mmol L1. V102862 shifted the steady-state
availability curve in the hyperpolarizing direction and significantly retarded recovery of
Na+ channels from inactivation. Thus, inhibition of voltage-gated Na+ channels is the
major mechanism underlying the anticonvulsant property of V102862. This agent also
displays ~80 fold higher affinity for inactivated Na+ channels compared to channels in
the resting state.
Yogeeswari et al. (55) studied the GABA level in different parts of the brain. N1-
(2,6-dimethylphenyl)-N4-(2-hydroxybenzaldehyde) semicarbazone increased the GABA
level by 118 % and inhibited the GABA transaminase enzyme both in vitro and in vivo.
N-(4-ethoxyphenyl)-N4-(2-hydroxyacetophenone) semicarbazone increased the GABA
level of the control only in the medulla oblongata region (49) (Fig. 13).
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Fig. 12. Rigid analogs of semicarbazones.
Cyclized semicarbazones such as 4-(2,4-dimethylphenyl)-5-(4-nitrophenyl)-2H-1,2,4-
-triazole also increased the GABA level more than 10 times compared to the control (83).
Some aryl-semicarbazones were shown to act through GABA mediation (86) (Fig. 13).
Apart from experimental evidence in favor of Na+ channel blockers and the GABA
mediated mechanism of action, other indirect evidences are also available. Arylsemicar-
bazones have been shown to protect against seizures induced by ScPTZ. ScPTZ tests re-
veal drugs likely to be active against absences, acting possibly as T-type calcium channel
blockers; ScSTY test indicates the compound is active through glycine receptors. PTZ or
picrotoxin (PIC) do not act through GABA-mediated inhibition (87, 88). They are non-
-competitive channel blockers. Ethosuxinimide, which is used in absence, reduces low
threshold (T-type) calcium channels. Ethosuxinimide protects ScPTZ induced seizures
(89). Among the large number of semicarbazones screened for channel activity, only two
compounds, 4-fluorophenoxy propiophenone semicarbazone(75) and 4-methylphenoxy-
acetophenone semicarbazone (76), were found activein the ScPTZ test, with ED50 values
of 12.8 and 19.2 mg kg1, respectively. This indicates that arylsemicarbazones will be
more beneficial for grandmal epilepsy. Similarly, only few compounds were active in
ScSTY and ScPTZ tests (Fig. 14).
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R = F, R1 = H
R = CH3, R1 = C2H5













Fig. 14. Anticonvulsants active against ScPTZ, ScBIC and ScSTY.
In the series of N-(2,6-dimethylphenyl) substituted semicarbazones, a large number
of compounds were found active at a dose of 30 mg kg1 in ScSTY tests. Therefore, these
compounds could be assumed to act through glycine receptors (55). A few compounds
(50) with p-nitrophenyl substitution also showed activity in ScSTY tests. Acetophenone
semicarbazone (73) and phenyl acetaldehyde semicarbazone (73) protected against sei-
zures induced by ScPTZ (ED50 60.75 mg kg1) and subcutaneous bicuculline (ScBIC)
(ED50 57.63 mg kg1) (Fig. 14).
Compound 4-({[2-(4-nitrobenzylidene)hydrazine]carbonyl}amino)-butanoic acid
(Fig. 15) was active in both ScSTY and ScPTZ tests at a dose of 30 mg kg1 (90).
Arylsemicarbazones can be predominantly used to treat grandmal epilepsy because
they are active against MES and have been shown to act through Na+ channel blocking.
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H-bonding area
Fig. 17. Dimmock’s revised model (75).
Pharmacophore model (91)
Based on the two schools of semicarbazone research, two models have been pro-
posed. In his initial work on semicarbazones, Dimmock (75) proposed a model with (i)
aryl binding site surrounded by an auxiliary binding area; (ii) hydrogen binding area
represented by a semicarbazono handle (Fig. 16). Based on new findings of aryl(oxy)
arylsemicarbazones as anticonvulsants (75), he modified the earlier model (Fig. 17) as
having: (i) aryl binding site (proximal aryl ring); (ii) distal aryl ring (distal binding site);
(iii) auxiliary binding area; (iv) semicarbazono handle as H-bonding area. It is important
to note that proximal rings are nearly coplanar with the ureido group (necessary for
H-bonding) (74).
Pandeya’s versatile model
Pandeya’s work (45, 50) mainly concentrated on the introduction of aryl/alkyl/
alicyclic moieties in the carboxamide amino function (38). This created another binding
site, distinct from Dimmock’s. The anticonvulsant activity of p-chlorophenyl/p-nitro-
phenyl/p-bromophenyl substituted semicarbazones was compared with active metabo-
lites of diazepam (92), nitrazepam and bromazepam (67) and clonazepam (Fig. 18).
Dimmock proposed the following structural features of an anticonvulsant: (i) aryl
binding site responsible for hydrophobic interaction (HPB site); (ii) two-electron donor
system (C=N); and most importantly (iii) a hydrogen bonding area as represented by
carboxamide CONH2 function (HBD).
This model can explain a number of AEDs such as safinamide, ezogabine and gaba-
pentin (Fig. 19). However, the model was not able to explain the AEDs having an aryl/
alkyl substituent (3, 18) in close proximity to the two-electron donor system, like pro-
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Fig. 18. Structural comparison of semicarbazones with benzodiazepines.
gabide, phenytoin, remacemide, levetiracetam, and arylsemicarbazones having substitu-
tion in the carboxamide amino function. Therefore, Pandeya (69) proposed a versatile
model to explain the anticonvulsant activity of a large number of AEDs. In addition to
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Fig. 19. Structural similarity of different clinically effective AEDs.
A: Hydrophobic bonding site(HPB)
HBD: Hydrogen bonding domain
D: Two electron donor group





A & C: Hydrophobic bonding
areas
B: Hydrogen bonding site
B C C
D
Fig. 20. Dimmock’s (91) vs. Pandeya’s (69) model.
the above mentioned three sites, an additional aryl/alkyl site was proposed as pharma-
cokinetic site. This site was responsible for the pharmacokinetic properties of the mole-
cule and included a phenyl ring with or without ortho substitution like benzodiazepines.
A comparison of the two models is given in Fig. 20.
Pandeya’s model can be thus adopted to design novel anticonvulsants having the
structural components of the proposed pharmacophore. It has also explained the phar-
macophore similarity of arylsemicarbazones to desmethyldiazepam. Semicarbazones
can be considered bioisosteric acyclic analogs of desmethyl diazepam (Fig. 21). The
–NH– of semicarbazones is bioisosteric with –CH2– of benzodiazepines. Also, semicar-
bazones can be considered acyclic analogs of cyclic benzodiazepines.
CONCLUSIONS
Semicarbazones have been developed as versatile anticonvulsant pharmacophores.
Two compounds, 4-(4-fluorophenoxy)benzaldehyde semicarbazone (FPBS) and N’-(4-
-chlorophenyl)-N4-(2-nitrobenzaldehyde) semicarbazone, have been identified as lead
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Fig. 21. Pandeya’s model compared with different AEDs (55).
molecules and are at various stages of development: FPBS is a sodium channel blocker
while the others are GABA transaminase inhibitors. Other mechanisms of action, like
glycine receptors and non-competitive channel blockers, have been proposed. A versa-
tile pharmacophore model has been suggested for future drug design and development
of anticonvulsants.
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S A @ E T A K
Semikarbazon – svestrani farmakofor u dizajniranju antikonvulziva
SURENDRA NATH PANDEYA
Tijekom posljednjih petnaest godina intenzivno su istra`ivana antikonvulzivna svoj-
stva semikarbazona. 4-(4-Flurofenoksi)benzaldehid semikarbazon (C0102862, V102862)
otkriven je kao vode}i spoj iz kojeg je razvijen antiepileptik s maksimalnom elektro{ok
aktivno{}u (MES) ED50 12,9 mg kg–1 (i.p.) i za{titnim indeksom (PI = TD50/ED50 > 315)
ve}im od karbamazepina (PI 101), fenitoina (PI > 21,6) i valproata (PI 2,17). Spoj je sna`-
ni blokator natrijevih kanala. Drugi su se semikarbazoni pokazali u~inkovitima u raz-
li~itim kemo-{ok testovima, kao {to su supkutana primjena pentilentetrazola, strihnina,
pikrotoksina i bikukulina. Semikarbazoni su tako|er inhibitori GABA-transaminaze.
Op{irne studije odnosa strukture i djelovanja pokazale su da je za antikonvulzivno dje-
lovanje bitna prisutnost F, Cl, Br i NO2 supstituenata u arilhidrofobnom d`epu i domena
za vezanje vodikovim vezama (HBD).
Klju~ne rije~i: semikarbazon, antikonvulziv, blokator Na+ kanala
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